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Abstract
Background: More women are requesting Emergency Hormonal Contraception (EHC) at
pharmacies where screening for Chlamydia trachomatis is not routinely offered. The objective of this
study was to assess the uptake of free postal chlamydia screening by women under 25 years who
requested EHC at pharmacies in Manchester, UK.
Methods: Six Primary Care Trusts (PCTs) that had contracted with pharmacies to provide free
EHC, requested the largest EHC providers (≥ 40 doses annually) to also offer these clients a coded
chlamydia home testing kit. Pharmacies kept records of the ages and numbers of women who
accepted or refused chlamydia kits. Women sent urine samples directly to the laboratory for
testing and positive cases were notified. Audit data on EHC coverage was obtained from PCTs to
assess the proportion of clients eligible for screening and to verify the uptake rate.
Results: 33 pharmacies participated. Audit data for 131 pharmacy months indicated that only
24.8% (675/2718) of women provided EHC were also offered chlamydia screening. Based on
tracking forms provided by pharmacies for the whole of the study, 1348/2904 EHC clients (46.4%)
who had been offered screening accepted a screening kit. 264 (17.6%) of those who accepted a kit
returned a sample, of whom 24 (9.1%) were chlamydia-positive. There was an increase in chlamydia
positivity with age (OR: 1.2 per year; 1.04 to 1.44; p = 0.015).
Conclusion: Chlamydia screening for EHC pharmacy clients is warranted but failure of
pharmacists to target all EHC clients represented a missed opportunity for treating a well defined
high-risk group.
Background
The National Chlamydia Screening Programme (NCSP) is
an opportunistic programme that offers screening to sex-
ually active men and women under the age of 25 in clini-
cal and non-clinical settings [1]. Prevalence of chlamydia
is highest in this young age group and more infections are
Published: 26 March 2009
BMC Women's Health 2009, 9:7 doi:10.1186/1472-6874-9-7
Received: 20 August 2008
Accepted: 26 March 2009
This article is available from: http://www.biomedcentral.com/1472-6874/9/7
© 2009 Brabin et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
BMC Women's Health 2009, 9:7 http://www.biomedcentral.com/1472-6874/9/7detected in healthcare settings than in the general popula-
tion [2]. Active case finding for genital chlamydia infec-
tion through screening of "at risk" populations can reduce
the prevalence of infection if coverage is sufficiently high
[3]. In pilot studies conducted prior to the introduction of
the NCSP in 2003, screening was taken up by about 50%
of sexually active women aged 16–24 years [4], a level not
achieved to date by the NCSP [1]. For transmission to fall,
the annual screening and testing rate of sexually active
young adults under 25 in a variety of healthcare and non-
healthcare settings (including tests at genitourinary medi-
cine clinics) must be sustained above 35%, together with
effective partner notification and management [5,6]. The
success of opportunistic screening depends on users
accessing services and adequate levels of awareness and
training of health providers [7]. Some researchers have
argued that more systematic approaches for calling and
recalling the target population would have a higher
impact on prevention of chlamydia-associated morbidity
than opportunistic screening [8]. Using general practi-
tioner registers to invite young men and women to return
home-collected samples [9] however, had a lower uptake
than expected. The most effective approaches for screen-
ing women for whom coverage is low have yet to be deter-
mined [10].
Meanwhile opportunistic screening at pharmacies has
been encouraged by the NCSP. Approximately 11% of
women and 14% of men accessed chlamydia screening at
pharmacies in 2006/07 [1] and a scheme was launched by
the Department of Health to assess uptake of free chlamy-
dia screening for both young men and women through
Boots pharmacies in 31 London Primary Care Trusts
(PCTs) [11]. Pharmacies have been increasing their range
of services and the government recognises them as a main-
stream contributor to primary care and public health [12].
Since 2000 EHC has become increasingly available from
pharmacies in a number of European countries, Canada,
New Zealand and Australia [13]. EHC is indicated to pre-
vent pregnancy after unprotected sexual intercourse,
which also exposes women to the risk of sexually trans-
mitted infections (STIs) [14-16]. In the UK, reclassifica-
tion of EHC from a "prescription only" to an "over the
counter" product in 2001 made EHC available on request.
This shift increased early access after unprotected sex, was
generally well accepted by the industry, and was well-
rated by women [17] although it had little impact on
unwanted pregnancy rates [18-20]. Within three years,
27% of EHC requests were handled through pharmacies
[21]. This shift in EHC provision away from sexual health
clinics increases the likelihood that this sub-group of high
risk women will not be screened for chlamydia. As such, a
targeted chlamydia case-finding approach among EHC
pharmacy clients might be appropriate. Pharmacists
involved in EHC schemes are trained to assess Fraser com-
petency of a minor (<16 years) to give informed consent
to medical treatment, and to advise on the risks of STIs
resulting from unprotected sex [20]. A pilot study in three
pharmacies in London, in which testing and treatment
were offered on site, suggested that chlamydia screening
was acceptable to pharmacists [22]. The purpose of our
study was to assess targeted delivery of free postal chlamy-
dia screening to women requesting EHC. Postal screening
was offered as pharmacies could offer this with little
inconvenience, and it would not require them to have on-
site facilities for sample collection.
Methods
The North West Multi Centre Research Ethics Committee
approved the study. The NCSP (which was locally known
as RUCLear) was rolled out gradually across England and
was not implemented in Manchester until December
2006. This allowed the study to be completed from Janu-
ary to December 2006 during the planning stages for its
introduction and in consultation with the RUClear co-
ordinator.
Selection of pharmacies
Patient group directions (PGD) constitute a legal frame-
work which allows certain health professionals to supply
medicines to groups of patients that fit the criteria laid out
in the PGD. PCTs are responsible for local pharmaceutical
services, and six PCTs in Manchester had contracted with
76 pharmacies to provide free EHC (progestogen-only
Levonelle-2) under a PGD to women under 25 [23]. The
PCTs requested pharmacies to also offer postal chlamydia
screening, although no additional remuneration was pro-
vided. A pragmatic decision was taken only to include
pharmacies that supplied at least 40 women with EHC per
year.
Procedures
Accredited EHC pharmacists were given additional train-
ing on chlamydia screening during EHC refresher courses
or individually by a sexual health research nurse (GT).
Pharmacists were instructed to offer the postal kit after
completing the EHC protocol when advising on STI risks,
and to explain the purpose and contents of the screening
kit. Testing kits were discretely packaged and contained an
information sheet, a consent form, a brief pre-piloted
questionnaire on symptoms, previous EHC use and
chlamydia treatment and demographic characteristics, as
well as instructions on taking and returning the sample to
the laboratory in the pre-paid envelope. Women were
advised to return the urine sample within two weeks.
Urines, rather than self taken swabs, were collected in line
with NCSP standard practice. Details of local sexual
health services were also provided. Each kit had a unique
number and central records were kept, indicating to which
pharmacy the kits had been issued and which kits werePage 2 of 6
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the numbers and age group of each EHC client, whether
she accepted or declined the screening offer, and the kit
number if accepted. These details were faxed to the
research nurse every month and she regularly visited all
pharmacies to ensure kits were available and to monitor
data recording. A face-to-face structured exit questionnaire
was conducted with all pharmacists who continued to the
end of the study and had not moved outside the area.
Laboratory tests and treatment
Urines, consent forms and questionnaires were returned
together to the Liverpool Specialist Virology Centre and
screened for the presence of Chlamydia trachomatis using
the Roche COBAS Taqman CT test (Roche Diagnostics
Ltd, Burgess Hill, UK) as described by the manufacturer.
All specimens identified as inhibitory or C. trachomatis
positive were retested using the Artus C. trachomatis Plus
PCR Kit after DNA isolation using a Qiagen M48 Biorobot
and Magattract Virus Mini M48 Kit (Qiagen Ltd, Crawley,
UK), both according to the manufacturer's instructions.
Questionnaires and consent forms were collected weekly
from the University of Liverpool but women were who
tested chlamydia-positive or were required to give another
sample were notified immediately. Participants could opt
for treatment by the research nurse at Manchester Centre
for Sexual Health or a family planning clinic. If the client
chose to book her own appointment, the research nurse
contacted the client to ensure she had attended and
received treatment and had been advised about treatment
of partners. Two participants were not treated because
they gave incorrect details and/or their GP (if they had
consented for GP contact) could not be traced.
Data analysis
It should have been possible to estimate the number of
eligible women treated from the tracking forms that phar-
macists had agreed to complete for all EHC clients but
17% of samples sent to the laboratory were not recorded
on these forms. Hence the number of women who were
offered EHC, who should have been given a screening kit,
was estimated from routine audit data collected by the
PCTs for the EHC programme. Due to PCT organisational
changes, not all the routine data could be accessed. The
denominator for Analysis (1), to determine the number of
women supplied with EHC who had been offered screen-
ing, was therefore based on an audit of those periods for
which the data were recorded by the PCTs. Analysis (2)
uses the denominator provided from the tracking forms to
determine the proportion of women who the pharmacist
recorded as accepting the screening kit. The number of
accepted kits is the denominator for analysis (3) which
describes the proportion of kits returned to the laboratory.
Binomial 95% confidence intervals were computed for
chlamydia prevalence. Where age data were grouped,
trends in age were assessed using logistic regression with
age group as the covariate. Logistic regression against cal-
endar age was used where individual data were available.
Results
There were 35 eligible pharmacies, and 33 participated in
the study. The types of pharmacy represented were 18
large chains (ie branch stores of large corporations), 12
independents, and 3 small chains. 15 were located in
shopping precincts or residential areas, 4 were attached to
surgeries and one was in a superstore. The majority (20)
had only one pharmacist. Six pharmacies interrupted or
ceased participation in both EHC provision and chlamy-
dia screening because the EHC-trained pharmacist moved
and was not replaced. One pharmacy withdrew early from
the study after its own brand of chlamydia testing kit went
on sale.
Audit of the proportion of kits offered to EHC clients
As described in the Methods section, audit data on the
number of EHC prescriptions by pharmacy, and hence the
number of eligible chlamydia screening clients, was avail-
able for a total of 131 pharmacy months (cf Methods,
Analysis 1). During those months covered by the audit
2718 women were given EHC but only 675 (24.8%) were
offered a chlamydia kit. Although under-16s were most
likely to have been offered a kit, there was no significant
trend with age (Table 1, logistic regression trend test, p =
0.13).
Kit acceptance and return rates estimated from pharmacy 
tracking forms
Over the period of the study, pharmacists recorded offer-
ing 2904 kits (cf. Methods, Analysis 2), which were
accepted by 1348 (46.4%) of women (Table 1). The
acceptance rate differed significantly by age group (Table
2) with older clients more likely to accept the offer of a kit
(p = 0.0005).
Only 236 (17.6%) of women who accepted a kit eventu-
ally returned a urine sample to the laboratory for testing
(cf Methods, Analysis 3). Additionally, on the form
returned with the kit, 13 gave their age as over 24 years,
which would have made them ineligible for the scheme.
There were no differences in return rates by age group.
Table 1: Age distribution of chlamydia screening kits offered to 
eligible EHC clients
ALL Under 16 16–19 20–24
Eligible 2718 * 205 1296 1217
Kits offered 675 65 321 289
% 24.8 31.7 24.8 23.7
* 4 eligible participants had missing age dataPage 3 of 6
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who returned urine samples
Six samples were inhibitory and four leaked. Clients were
re-contacted and seven repeat samples obtained and
retested (one positive), giving 264 test results. In total, 24/
264 (9.1%) samples were positive and the number of pos-
itives increased with age (Table 3, Trend test, p = 0.031).
A logistic regression using actual, rather than grouped,
ages showed a significant increase in positive tests with
age (OR = 1.2 per year, 95% CI: 1.04 to 1.44; p = 0.015).
Discussion
Women requesting EHC who have had unprotected sex,
represent a discrete target group for chlamydia screening.
In this operational study, designed to determine the
uptake of screening in routine practice, only 25% of eligi-
ble clients were offered a postal kit. Older women were
significantly more likely to accept the offer of a screening
kit and had a higher risk of testing positive but were
offered the lowest number of kits. The main rationale for
making screening a priority in pharmacies is that it would
be offered if the EHC request had been made in a clinical
setting. Women who have accessed EHC in pharmacies
may not refer themselves for testing.
The success of opportunistic screening depends on the
assiduity of the health provider [7]. A strength of this
study is that we have been able to demonstrate that phar-
macists, though willing to provide EHC, did not consist-
ently offer chlamydia screening. We tracked protocol
deviations through the coding system so could quantify
and allow for incomplete data recording by pharmacists.
The EHC audit data provided an independent assessment
of the proportion of missed opportunities. The audit did
not cover the whole study period, but there is no reason
to suspect that the periods covered were not representa-
tive. The audit indicated that pharmacists were not com-
pleting tracking forms for EHC clients who had not been
offered chlamydia screening. Other postal screening stud-
ies that offered kits, either exclusively or partly through
pharmacies, have relied on the numbers of kits distributed
and returned as performance indicators [24,25] and did
not assess the extent of missed screening opportunities. It
should be acknowledged, however, that pharmacists may
have been more assiduous in offering screening had they
entered into a formal agreement with the local NCSP pro-
gramme, or had they been offered additional financial
incentives. This study predated the NSCP and did not
include measures to raise awareness of the screening and
its availability. It is possible that with greater awareness
amongst women that uptake would be higher. Neverthe-
less, the Boots study in London, which took place after the
NCSP started, also found that pharmacists were not pro-
active in offering screening but waited to be asked for a kit
by clients [11]. Selectivity or forgetfulness is avoided in
schemes offering systematic screening – when a target
population, defined by age, is contacted at defined inter-
vals [26,27]. Consistency is more difficult to measure and
address in busy commercial settings such as pharmacies,
especially those with a high turn-over of pharmacists. In
our study most pharmacies had only one EHC-accredited
pharmacist and some of these left, causing both EHC pro-
vision and screening to halt.
Approximately a half of EHC clients accepted a kit but
only 17% returned a sample. Some women may have felt
obliged to take the kit without necessarily perceiving
themselves to be at risk [28] or they may not have wished
to consider their risk of chlamydia in the context of an
EHC visit. For ethical reasons, it is difficult to find out why
Table 2: Proportion of kits offered to EHC clients (based on pharmacy reports) and returned to the laboratory for C. trachomatis 
testing
ALL Under 16 16–19 20–24 p-value #
Kits offered 2904 374 1197 1333
Kits accepted 1348 (46.4%) 116 (31.0%) 566 (47.3) 666 (50.0%) 0.0005







+ 7 kits were improperly recorded and were untraceable
# Trend test for age using logistic regression
Table 3: Numbers testing positive for C. trachomatis by age group
ALL Under 16 16–19 20–24
Number of test results 264 20 119 125
Number Positive (%) 24 (9.1%) 1 (5%) 6 (5.0%) 17 (13.6%)
95% CI* 6.2 to 13.2% 0.3 to 23.6% 2.3 to 10.6% 8.7 to 20.7%
*CI: Confidence intervalsPage 4 of 6
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the main reasons that EHC clients refused chlamydia
screening was recent prior testing [15,22]. The higher test-
ing rate (over 50%) in the Department of Health Boots
study may have been because more women actively
requested screening kits [11]. They may have perceived
themselves to be at risk or had symptoms, and so were
more motivated to return a sample. We do not know why
women take kits but do not return them but it is likely to
reflect the quality of counselling provided, women's
understanding of the purpose and importance of testing
and their sense of obligation [29]. On-site testing would
eliminate the waste associated with postal kits, and might
encourage women for whom convenience of testing is
important. It would, however, limit the range of pharma-
cies that could offer screening to those with facilities for
urine collection.
The positivity rate for chlamydia was 9% but among
Dutch 15–24 year olds who accepted a postal kit after col-
lecting contraceptives at a pharmacy in a high risk-setting,
14% tested positive [25]. It is not always easy to identify
high-risk settings, but selecting pharmacies to deliver
chlamydia testing might be more productive, especially if
the pharmacists were offered enhanced training. A review
of educational strategies targeting primary care providers
with a view to improving chlamydia screening rates indi-
cated that the method and intensity of training is impor-
tant [7]. In exit interviews 20/26 pharmacists admitted
selectively offering screening to EHC clients who they
thought would be more likely to have chlamydia. They
mainly based this risk assessment on whether or not they
perceived the client to be in a stable relationship. Their
attitudes will be reported in detail in a separate qualitative
study report. Pharmacists' selection of clients to be offered
kits undermines the principles of an opportunistic screen-
ing programme where the onus is on the health profes-
sional to be actively case-finding in a population that may
be unaware of the risk of infection [30].
Conclusion
Targeted chlamydia screening represents a logical addi-
tion to the EHC protocol in pharmacies offering this serv-
ice. Failure to offer screening to all EHC clients represents
a missed opportunity for treating a well-defined high-risk
group.
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